Do antidepressants, particularly SSRIs and SNRIs, cause bone loss or increase fracture risk?

Antidepressants and Bone Health: Evidence-Based Assessment

Yes, antidepressants—particularly SSRIs and SNRIs—cause bone loss and significantly increase fracture risk, with current users experiencing up to a 2.5-fold increased risk of hip fracture and measurable decreases in bone mineral density across all skeletal sites. 1, 2

Mechanism of Bone Damage

Antidepressants affect bone through direct biological pathways, not just through increased fall risk:

• Serotonin receptors are present on all major bone cells (osteoblasts, osteocytes, and osteoclasts), and SSRIs increase serotonin levels, resulting in decreased osteoblast activity and subsequent bone loss 3
• SSRIs with high affinity for the serotonin transporter system show the strongest association with bone loss, suggesting a dose-response relationship tied to drug mechanism rather than depression severity alone 4
• Bone mineral density decreases are measurable across all skeletal sites, with standardized mean differences ranging from -0.02 at the total hip to -0.04 at the femoral neck compared to non-users 2

Fracture Risk: Magnitude and Timeline

The fracture risk is substantial and follows a specific temporal pattern:

• Current SSRI/SNRI use increases fracture risk 1.68 to 2.5-fold even after controlling for depression severity, fall history, bone mineral density, and other confounders 5, 2
• Risk peaks dramatically early in treatment: within 1 month for tricyclic antidepressants and 8 months for SSRIs 4
• The increased risk diminishes toward baseline within one year following discontinuation, indicating the effect is medication-related rather than solely disease-related 4
• Acute bleeding complications occur in the first postoperative week (days 1-7) following fracture surgery in SSRI/SNRI users, with higher rates of post-hemorrhagic anemia (18% vs 16%) and transfusion requirements (9.5% vs 8.0%) 6

Drug-Specific Risk Profiles

Not all antidepressants carry equal risk:

Higher Risk Agents:

• Citalopram (HR 1.23-1.43), sertraline (HR 1.36), duloxetine (HR 1.41), doxepin (HR 1.36), and imipramine (HR 1.16) show consistently elevated fracture risk across multiple jurisdictions 7
• SSRIs as a class demonstrate osteopenic bone density values in users 8

Lower Risk Alternatives:

• Paroxetine shows lower fracture risk than citalopram among SSRIs 7
• Venlafaxine carries lower risk than duloxetine among SNRIs 7
• Amitriptyline has lower risk than imipramine or doxepin among tricyclics 7
• SNRIs may have lower overall osteoporosis risk than SSRIs, with duloxetine appearing safer than venlafaxine (duloxetine users maintain normal lumbar T-scores while venlafaxine users show osteopenic values) 8

Critical Risk Factors That Amplify Fracture Risk

When antidepressants are combined with certain comorbidities, fracture risk multiplies:

• Osteoporosis increases fracture risk 3-fold (aOR 3.05) in antidepressant users 9
• History of falling increases fracture risk 6-fold (aOR 6.13) in antidepressant users 9
• Proton pump inhibitors (commonly co-prescribed) further decrease calcium absorption and independently increase fracture risk 3
• Long-term glucocorticoid use is an established fracture risk factor that may be present in patients requiring antidepressants 10, 11

Clinical Management Algorithm

For Patients Requiring Antidepressants:

1. Assess baseline fracture risk before initiating therapy using clinical fracture assessment, bone mineral density with vertebral fracture assessment, and FRAX if ≥40 years old 11

2. Choose the lowest-risk antidepressant based on the evidence:

   • Prefer paroxetine over citalopram or sertraline among SSRIs 7
   • Prefer venlafaxine over duloxetine among SNRIs 7
   • Consider duloxetine if SNRI is required and bone health is a primary concern 8

3. Implement bone protection immediately for patients at moderate-to-high fracture risk:

   • Calcium 1,200 mg/day and vitamin D ≥1,000 IU/day for all patients 12, 11
   • Add bisphosphonate therapy (alendronate, risedronate, or zoledronic acid preferred) for those with T-score ≤-2.5 or FRAX 10-year major osteoporotic fracture risk ≥20% or hip fracture risk ≥3% 13, 12

4. Monitor bone density every 1-2 years during antidepressant therapy, particularly in the first 8 months when fracture risk peaks 12, 4

5. Implement fall prevention strategies including weight-bearing, balance, and resistance exercises, as the combination of antidepressant use and fall history creates multiplicative risk 12, 3

Common Pitfalls to Avoid:

• Do not assume depression alone explains fracture risk—the medications themselves have direct bone effects independent of depression severity 4
• Do not delay bone protection until after the first fracture—risk is highest in early treatment when intervention is most critical 4
• Do not ignore the interaction between SSRIs and PPIs—this combination creates additive bone loss through decreased calcium absorption 3
• Do not continue high-risk antidepressants indefinitely without reassessing—fracture risk diminishes after discontinuation 4

For Patients Already on Antidepressants with New Fractures:

• Expect increased acute bleeding complications in the first postoperative week (days 1-7) following fracture fixation, with higher transfusion requirements 6
• Strongly recommend pharmacologic osteoporosis treatment with bisphosphonates for 5 years following fracture 13
• Consider switching to lower-risk antidepressants if mental health status permits 7